08:10 AM EDT, 05/20/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) on Tuesday said it has signed an agreement with a pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the U.S. Food & Drug Administration.

A successful IND application will allow Quantum Biopharma ( QNTM ) to move forward with a Phase 2 trial of Lucid-21-302 in people with multiple sclerosis (MS). The company hopes to submit the application in the fourth quarter of this year.

"This agreement takes us a step closer to initiating the phase 2 trial of Lucid-21-302, a first-in-class treatment for MS," said Chief Executive Zeeshan Saeed.